Nintedanib (Ofev) is a targeted drug used for the treatment of idiopathic pulmonary fibrosis (IPF). It slows down disease progression by inhibiting a variety of tyrosine kinases. Its clinical use may be accompanied by a series of adverse reactions, some of which may even be life-threatening.
What Are the Side Effects of Nintedanib (Ofev)?
Gastrointestinal Reactions
Frequently occurring symptoms: Diarrhea (62%), nausea (24%), abdominal pain (15%), and vomiting (12%).
Characteristics: Most occur in the early stage of treatment (first 3 months), and most are mild to moderate. However, they may lead to dose adjustments (11% of patients have dose reduction due to diarrhea) or treatment discontinuation (5% of patients stop treatment due to diarrhea).
Abnormal Liver Function
14% of patients experience elevated liver enzymes (ALT/AST), and 3% have elevated bilirubin.
Regular monitoring is required: Testing should be conducted before medication use, monthly within 3 months after starting medication, and then rechecked every 3 months thereafter.
Other Common Reactions
Decreased appetite (11%), weight loss (10%), headache (8%), and hypertension (5%).
Severe Side Effects of Nintedanib (Ofev) That Require Vigilance
Risk of Hepatotoxicity
It may progress to severe liver injury, manifested as jaundice, dark-colored urine, or right upper abdominal pain.
If ALT/AST is more than 5 times the normal value or accompanied by jaundice, permanent drug discontinuation is required.
Arterial Thrombotic Events
The incidence of myocardial infarction is 1.5% (0.4% in the placebo group). Patients with coronary heart disease need to be cautious. If chest pain or dyspnea occurs, medical attention should be sought immediately.
Bleeding and Gastrointestinal Perforation
The incidence of bleeding events is 10% (7% in the placebo group), and the incidence of gastrointestinal perforation is 0.3%.
For patients who have undergone recent abdominal surgery or are receiving anticoagulant therapy, the pros and cons need to be weighed.
Embryotoxicity
Animal experiments have shown teratogenicity. Women of childbearing age need to use contraception until 3 months after drug discontinuation, and the drug is contraindicated during pregnancy.
Precautions for Nintedanib (Ofev) Administration
Dosage and Administration Method
Standard dosage: 150mg twice a day (with an interval of 12 hours), taken with meals to reduce gastrointestinal irritation.
Management of missed doses: Skip the missed dose; do not make up for it or take a double dose.
Dosage Adjustments for Special Populations
Hepatic insufficiency: Close monitoring is required for patients with mild hepatic insufficiency (Child-Pugh Class A); the drug is contraindicated for patients with moderate to severe hepatic insufficiency (Child-Pugh Class B/C).
Smokers: Smoking reduces drug exposure, so smoking cessation is recommended.
Drug Interactions
Contraindicated combinations: Strong CYP3A4/P-gp inducers (such as rifampicin, St. John's wort) can reduce the efficacy of nintedanib.
Combinations requiring caution: Concurrent use with anticoagulants increases the risk of bleeding, so close monitoring is necessary.
Lifestyle Management Recommendations
Management of diarrhea: When diarrhea occurs for the first time, use loperamide and replenish fluids immediately. For persistent and severe diarrhea, treatment interruption is required.
Sun protection measures: Patients with photosensitivity reactions need to use sunscreen with SPF 50+ and avoid sun exposure.
